MOTRIN COLD & SINUS PAIN TABLET

Land: Canada

Taal: Engels

Bron: Health Canada

Werkstoffen:

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

Beschikbaar vanaf:

MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC

ATC-code:

M01AE51

INN (Algemene Internationale Benaming):

IBUPROFEN, COMBINATIONS

Dosering:

200MG; 30MG

farmaceutische vorm:

TABLET

Samenstelling:

IBUPROFEN 200MG; PSEUDOEPHEDRINE HYDROCHLORIDE 30MG

Toedieningsweg:

ORAL

Eenheden in pakket:

20/40

Prescription-type:

OTC

Therapeutisch gebied:

ALPHA-AND BETA-ADRENERGIC AGONISTS

Product samenvatting:

Active ingredient group (AIG) number: 0222394001; AHFS:

Autorisatie-status:

CANCELLED POST MARKET

Autorisatie datum:

2016-08-05

Productkenmerken

PRODUCT MONOGRAPH
MOTRIN® COLD & SINUS PAIN
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE TABLETS, U.S.P.
TABLETS
THERAPEUTIC CLASSIFICATION
ANALGESIC/ANTIPYRETIC/NASAL DECONGESTANT
MCNEIL CONSUMER HEALTHCARE
DATE OF REVISION:
88 MCNABB STREET
FEBRUARY 26, 2009
MARKHAM, ONTARIO L3R 5L2
SUBMISSION CONTROL NUMBER: 128263
- 2 -
TABLE OF CONTENTS
I.
Clinical
Pharmacology.........................................................................................................3
II.
Indications............................................................................................................................8
III.
Contraindications
.................................................................................................................8
IV.
Warnings..............................................................................................................................9
V.
Precautions...........................................................................................................................9
VI.
Drug Interactions
...............................................................................................................10
VII.
Adverse Reactions
.............................................................................................................12
VIII.
Dosage and Administration
...............................................................................................17
IX.
Pharmaceutical
Information...............................................................................................18
X.
Availability of Dosage
Forms............................................................................................20
XI.
Information for the Consumer
...........................................................................................20
XII.
Overdosage
........................................................................................................................22
XIII.
Pharmacology
...........................................................................